ProShare Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-18,615
| Closed | -$55K | – | 1776 |
|
|
2016
Q3 | $55K | Sell |
18,615
-3,345
| -15% | -$5.8K | ﹤0.01% | 1440 |
|
|
2016
Q2 | $33K | Sell |
21,960
-2,369
| -10% | -$5.42K | ﹤0.01% | 1570 |
|
|
2016
Q1 | $90K | Sell |
24,329
-2,594
| -10% | -$16.1K | ﹤0.01% | 1527 |
|
|
2015
Q4 | $272K | Buy |
26,923
+2,701
| +11% | +$32.5K | ﹤0.01% | 1345 |
|
|
2015
Q3 | $329K | Sell |
24,222
-1,772
| -7% | -$31.6K | ﹤0.01% | 1107 |
|
|
2015
Q2 | $493K | Sell |
25,994
-2,610
| -9% | -$56.5K | 0.01% | 1098 |
|
|
2015
Q1 | $749K | Buy |
28,604
+3,441
| +14% | +$87.6K | 0.01% | 993 |
|
|
2014
Q4 | $527K | Sell |
25,163
-1,774
| -7% | -$44.7K | 0.01% | 1171 |
|
|
2014
Q3 | $899K | Sell |
26,937
-6,285
| -19% | -$195K | 0.01% | 1110 |
|
|
2014
Q2 | $1.07M | Sell |
33,222
-19,240
| -37% | -$716K | 0.01% | 1127 |
|
|
2014
Q1 | $2.42M | Buy |
52,462
+36,699
| +233% | +$2.15M | 0.03% | 634 |
|
|
2013
Q4 | $1.12M | Sell |
15,763
-13,252
| -46% | -$1.01M | 0.02% | 950 |
|
|
2013
Q3 | $2.49M | Buy |
29,015
+5,182
| +22% | +$439K | 0.06% | 318 |
|
|
2013
Q2 | $1.51M | Buy |
+23,833
| New | +$1.27M | 0.03% | 601 |
|
ProShare Advisors's AEGR Position: Q4 2016 in Review
ProShare Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 18,615 shares — an estimated $55K sold.
ProShare Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $2.49M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- ProShare Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- ProShare Advisors sold 18,615 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $55K.
- ProShare Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- ProShare Advisors's Aegerion Pharmaceuticals position peaked at $2.49M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on ProShare Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.